- Home
- PHAR vs EQBK Comparison
PHAR vs EQBK Comparison
Compare PHAR & EQBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAR | EQBK |
|---|---|---|
| Founded | 1988 | 2002 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 800.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | PHAR | EQBK |
|---|---|---|
| Price | $17.19 | $46.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $38.00 | ★ $47.80 |
| AVG Volume (30 Days) | 22.5K | ★ 79.3K |
| Earning Date | 11-06-2025 | 01-21-2026 |
| Dividend Yield | N/A | ★ 1.57% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.00 | ★ 1.00 |
| Revenue | ★ $362,274,000.00 | $186,035,000.00 |
| Revenue This Year | $24.80 | $15.54 |
| Revenue Next Year | $6.84 | $37.88 |
| P/E Ratio | $2,946.57 | ★ $45.62 |
| Revenue Growth | ★ 26.78 | 17.93 |
| 52 Week Low | $7.50 | $34.11 |
| 52 Week High | $18.12 | $48.14 |
Technical Indicators
Market Signals| Indicator | PHAR | EQBK |
|---|---|---|
| Relative Strength Index (RSI) | 55.30 | 62.04 |
| Support Level | $16.15 | $44.38 |
| Resistance Level | $17.00 | $48.14 |
| Average True Range (ATR) | 0.71 | 1.54 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 61.04 | 62.69 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.